Lipoprotein(a) is a presumed risk factor for atherosclerotic cardiovascular disease. Olpasiran is a small interfering RNA that reduces lipoprotein(a) synthesis in the liver. We conducted a randomized, ...

In a recent study published in the journal Current Medical Research and Opinion, researchers report that high lipoprotein(a) levels were linked to repeated coronary heart disease events in older ...

"Cardiovascular disease remains the world's leading cause of death, yet elevated Lp (a), a highly prevalent risk factor, is not even on most people's radar," said Neil Johnson, Executive Director of ...

Elevated lipoprotein(a) concentrations are associated with atherosclerotic cardiovascular disease. The safety and efficacy of lepodisiran, an extended-duration, small interfering RNA targeting hepatic ...

A new analysis has uncovered a potential link between higher prostate cancer risk and genetic variants associated with higher bloodstream levels of the cholesterol-transporting molecule lipoprotein A.